Saturday, August 21, 2021 8:51:42 PM
Nymox Announces Date for Fexapotide Filing
NEWS RELEASE
HASBROUCK HEIGHTS, NJ (May 6, 2021) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 September 2021.
CEO Dr Paul Averback said, "The Company will file on or before September 15. We hope but cannot be certain that the date may be before September. Company management will communicate updates where appropriate."
https://nymox.com/files/download/45b2b195922068b
Recent NYMXF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 07:36:48 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM